Pharmacokinetic-Pharmacodynamic Relationships of Apomorphine in Patients with Parkinson's Disease

By Neef C.  

Clinical Pharmacokinetics, Vol. 37, Iss. 3, 1999-09 ,pp. : 257-271

Adis International

Access to resources Recommend Favorite

Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson’s Disease

By Chan Phylinda   Nutt John   Holford Nicholas  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 32, Iss. 3-4, 2005-08 ,pp. : 459-484

Springer Publishing Company

Access to resources Recommend Favorite

Vancomycin Dosage Optimization in Patients with Malignant Haematological Disease by Pharmacokinetic/Pharmacodynamic Analysis

By >   >   Navarro Amparo Sánchez   Dominguez-Gil Alfonso   >  

Clinical Pharmacokinetics, Vol. 48, Iss. 4, 2009-06 ,pp. : 273-280

Adis International

Access to resources Recommend Favorite

Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis

By  

Fundamental & Clinical Pharmacology, Vol. 30, Iss. 5, 2016-10 ,pp. : 459-465

John Wiley & Sons Inc

Access to resources Recommend Favorite

The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations

By Stocchi Fabrizio  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 10, 2006-07 ,pp. : 1399-1407

Informa Healthcare

Access to resources Recommend Favorite